Opthea to Present at the 10th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Opthea Limited (ASX:OPT, Nasdaq: OPT) announced that CEO Dr. Megan Baldwin will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference on Feb 24, 2021, at 3:40pm ET. The presentation will focus on Opthea's novel therapy for retinal diseases, particularly wet age-related macular degeneration and diabetic macular edema. A live webcast will be accessible via their Investors page. Investors are cautioned about the inherent risks in biotechnology investments, including lengthy clinical trials and regulatory approvals.

MELBOURNE, Australia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announced that Dr Megan Baldwin, CEO of Opthea, will virtually present and provide a corporate update at the 10^th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 3:40pm ET (Thursday, February 25, 2021 at 7:40am AEDT).

A live webcast of the presentation will be available on the Investors page of the Opthea website at https://www.opthea.com/presentations/.

About Opthea

Opthea (ASX:OPT, Nasdaq: OPT) is a biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

Forward-looking Statements

Certain statements in this announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, regarding the Company’s business as well as the proposed Offering. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including market conditions, the satisfaction of customary closing conditions relating to the Offering and the impact of general economic, industry or political conditions in Australia, the United States or internationally. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the Offering to be filed with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements as predictions of future events, which statements apply only as of the date of this announcement. Actual results could differ materially from those discussed in this ASX announcement.

Company & Media Enquiries:	Join our email database to receive program updates:
Megan Baldwin, PhD	Tel: +61 (0) 3 9826 0399
CEO & Managing Director	info@opthea.com
Opthea Limited	www.opthea.com
Tel: +61 (0) 447 788 674
megan.baldwin@opthea.com
Australia:	U.S.A. & International:
Rudi Michelson	Jason Wong
Monsoon Communications	Blueprint Life Science Group
Tel: +61 (0) 3 9620 3333	Tel: +1 415 375 3340, Ext 4
	Jwong@bplifescience.com

FAQ

When is Opthea's corporate update presentation scheduled for 2021?

Opthea's corporate update presentation is scheduled for February 24, 2021, at 3:40pm ET.

Where can I watch Opthea's presentation at the SVB Leerink Global Healthcare Conference?

You can watch Opthea's presentation live on their Investors page at www.opthea.com.

What is the focus of Opthea's presentation at the upcoming conference?

The focus of Opthea's presentation will be on their novel therapy for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.

What are the risks associated with investing in Opthea (OPT)?

Investing in Opthea involves risks such as the lengthy clinical trial process, regulatory approvals, and uncertainties related to product development.

What is the lead product candidate of Opthea?

Opthea's lead product candidate is OPT-302, aimed to enhance the treatment of retinal diseases.